NCT05983133: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors

Sponsor: Seagen, a wholly owned subsidiary of Pfizer. Phase: PHASE1. Conditions: Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma